The DOI matches its Crossref record.
Characterization of an azole-resistant Candida glabrata isolate
Open accessAbstract
A Candida (Torulopsis) glabrata strain (B57149) became resistant to fluconazole after a patient carrying the organism was treated with the drug at 400 mg once daily for 9 days. Growth of the pretreatment isolate (B57148) was inhibited by 50% with 0.67 microM ketoconazole, 1.0 microM itraconazole, and 43 microM fluconazole, whereas growth of B57149 was inhibited slightly by 10 microM ketoconazole but was unaffected by 10 microM itraconazole or 100 microM fluconazole. This indicates cross-resistance to all three azole antifungal agents. The cellular fluconazole content of B57149 was from 1.5- to 3-fold lower than that of B57148, suggesting a difference in drug uptake between the strains. However, this difference was smaller than the measured difference in susceptibility and, therefore, cannot fully explain the fluconazole resistance of B57149. Moreover, the intracellular contents of ketoconazole and itraconazole differed by less than twofold between the strains, so that uptake differences did not account for the azole cross-resistance of B57149. The microsomal cytochrome P-450 content of B57149 was about twice that of B57148, a difference quantitatively similar to the increased subcellular ergosterol synthesis from mevalonate or lanosterol. These results indicate that the level of P-450-dependent 14 alpha-demethylation of lanosterol is higher in B57149. Increased ergosterol synthesis was also seen in intact B57149 cells, and this coincided with a decreased susceptibility of B57149 toward all three azoles and amphotericin B. B57149 also had higher squalene epoxidase activity, and thus, more terbinafine was needed to inhibit the synthesis of 2,3-oxidosqualene from squalene. P-450 content and ergosterol synthesis both decreased when isolate B57149 was subcultured repeatedly on drug-free medium. This repeated subculture also fully restored the strain's itraconazole susceptibility, but only partly increased its susceptibility to fluconazole. The results suggest that both lower fluconazole uptake and increased P-450-dependent ergosterol synthesis are involved in the mechanism of fluconazole resistance but that only the increased ergosterol synthesis contributes to itraconazole cross-resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“Increased expression of ERG11 has been observed in only two clinical isolates of C. glabrata (vanden Bossche et al., 1992; Redding et al., 2003).”
BackgroundResistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Potential Role of Phospholipases in Virulence and Fungal Pathogenesis
Ghannoum, M. A. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.1.122 · Cited by 818
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Itraconazole resistance in Aspergillus fumigatus
Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A., Warnock, D. W., & Kelly, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1364 · Cited by 508
Nosocomial Candidiasis: Emerging Species, Reservoirs, and Modes of Transmission
Pfaller, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s89 · Cited by 502
Antifungal agents: chemotherapeutic targets and immunologic strategies
Georgopapadakou, N. H., & Walsh, T. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.279 · Cited by 498
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Self-citationGroll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Antifungal susceptibility testing
Rex, J. H., Pfaller, M. A., Rinaldi, M. G., Polak, A., & Galgiani, J. N. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.367 · Cited by 361
Selmecki, A. M., Dulmage, K., Cowen, L. E., Anderson, J. B., & Berman, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000705 · Cited by 319
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
An update on antifungal targets and mechanisms of resistance in Candidaalbicans
Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291
Molecular mechanisms of drug resistance in fungi
Vanden Bossche, H., Marichal, P., & Odds, F. C. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90618-1 · Cited by 254
Self-citationMolecular biological characterization of an azole-resistant Candida glabrata isolate
Marichal, P., Vanden Bossche, H., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V, Van Broeckhoven, C., Fay, S., & Mose-Larsen, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2229 · Cited by 210
Self-citationGeber, A., Hitchcock, C. A., Swartz, J. E., Pullen, F. S., Marsden, K. E., Kwon-Chung, K. J., & Bennett, J. E. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2708 · Cited by 203
Kaur, R., Castaño, I., & Cormack, B. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1600-1613.2004 · Cited by 167
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
Mechanisms of Azole Resistance in Petite Mutants of Candida glabrata
Brun, S., Bergès, T., Poupard, P., Vauzelle-Moreau, C., Renier, G., Chabasse, D., & Bouchara, J.-P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1788-1796.2004 · Cited by 151
Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750
Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1578-1584.2000 · Cited by 145
Bennett, R. J., Forche, A., & Berman, J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019604 · Cited by 118
Wakabayashi, H., Abe, S., Okutomi, T., Tansho, S., Kawase, K., & Yamaguchi, H. (1996) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1996.tb01147.x · Cited by 116
White, T., Pfaller, M., Rinaldi, M., Smith, J., & Redding, S. (1997) · Oral Diseases · doi:10.1111/j.1601-0825.1997.tb00336.x · Cited by 107
Ksiezopolska, E., Schikora-Tamarit, M. À., Beyer, R., Nunez-Rodriguez, J. C., Schüller, C., & Gabaldón, T. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.084 · Cited by 107
Azole Resistance in Candida glabrata
Whaley, S. G., & Rogers, P. D. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0554-5 · Cited by 85
In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata
DEFONTAINE, A., BOUCHARA, J.-P., DECLERK, P., PLANCHENAULT, C., CHABASSE, D., & HALLET, J.-N. (1999) · Journal of Medical Microbiology · doi:10.1099/00222615-48-7-663 · Cited by 65
A Double-Edged Sword: Aneuploidy is a Prevalent Strategy in Fungal Adaptation
Tsai, H.-J., & Nelliat, A. (2019) · Genes · doi:10.3390/genes10100787 · Cited by 60
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1997) · Clinical Infectious Diseases · doi:10.1086/515554 · Cited by 54
“Mechanisms of resistance demonstrated to date have included efflux pumps [17], enzyme mutations [18, 19], and overproduction of target enzymes [20].”
Background
Metadata
- Authors
- vanden Bossche, H., Marichal, P., Odds, F. C., Le Jeune, L., & Coene, M. C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1992-12
- Volume
- 36
- Issue
- 12
- Pages
- 2602-2610
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2150252559
- Cited by
- 203
- References
- 0
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.